Navigation Links
Asymmetrex’s Plan for Free Stem Cell Counting Is The Feature Story by Superb Crew News
Date:6/23/2020

In its June 22 online post, business and technology news platform Superb Crew reported its feature interview with Dr. James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex. Superb Crew decided to highlight Asymmetrex after the company announced on June 16 that starting July 5 it would begin offering free tissue stem cell counting at its company website.

In the interview, Sherley discussed Asymmetrex’s tissue stem cell counting technology with the perspective that it is a very recent development for the industry. He noted that, like many new transformative biotechnologies, it and its value are not yet widely known. The planned free stem cell counting site is a part of Asymmetrex’s greater vision to increase academic and industry awareness of the need for tissue stem cell counting and its value, while at the same time making it readily available for immediate practice.

An earlier podcast series on “Counting Stem Cells” featured on the international stem cell industry networking platform RegMedNet, relates the many benefits of Asymmetrex’s technology for stem cell research, stem cell medicine, tissue stem cell biomanufacturing, pharmaceutical development, and environmental health science. By getting the technology out into use for free, Asymmetrex plans to “ignite a widespread adoption of tissue stem cell counting as [the] new normal” for tissue stem cell research, stem cell medicine, and drug development.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dosage and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies, cell biomanufacturing, and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Read the full story at https://www.prweb.com/releases/asymmetrexs_plan_for_free_stem_cell_counting_is_the_feature_story_by_superb_crew_news/prweb17210121.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Counting the invisible by sound -- a new approach to estimate seabird populations
2. Counting down to FEBS-EMBO 2014 in Paris, France
3. Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation
4. Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells
5. Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells
6. Asymmetrex Announces New Algorithms for Rapid Low Cost Counting of Therapeutic Tissue Stem Cells
7. Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting
8. Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP
9. Medbox Featured in Bloomberg Businessweek
10. Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system
11. Fluke Biomedical launches portable, feature-rich ProSim 3 and 2 Vital Signs Simulators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/28/2020)... , ... June 25, 2020 ... ... enterprise software solutions for biopharmaceutical R&D, today announced that it has entered ... innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical research ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands ... , Known as MediVet Biologics since its formation in 2016, the company is ... Animal Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter maintenance and ... successful study, while protecting and accessing the catheter or device post-surgery is often undervalued ... Envigo in a live webinar on Wednesday, August 5, 2020 at ...
(Date:7/10/2020)... (PRWEB) , ... July 09, ... ... biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded ... broader license allows PathSensors to move into the point-of-care diagnostic market, focusing ...
Breaking Biology Technology: